Biotech · Private company
Accent Therapeutics
Track this companyFree. Adds Accent Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- ATX-295Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ATX-295 and bevacizumab (or biosimilar)Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ATX-559Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerPHASE1_PHASE2 · RECRUITING · started Mar 21, 2025ClinicalTrials.gov NCT06799065 · fetched Nov 12, 2026
- First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersPHASE1 · TERMINATED · started Oct 11, 2024ClinicalTrials.gov NCT06625515 · fetched Nov 12, 2026